The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
Nils Glenjen
No relevant relationships to disclose
Katrin Hammerling
No relevant relationships to disclose
Ingunn Hatlevoll
No relevant relationships to disclose
Rune Småland
No relevant relationships to disclose
Petra Weber Hauge
No relevant relationships to disclose
Geir Egil Eide
No relevant relationships to disclose
Halfdan Sorbye
No relevant relationships to disclose
Olav Dahl
No relevant relationships to disclose
Gunilla Frykholm
No relevant relationships to disclose